 Phase IIa randomized, double blind, placebo-controlled, clinical trial of LACTIN-V at 2 x 109 cfudose versus placebo, administered vaginally with a pre-filled applicator once daily for five consecutive days followed by a weekly dose over 2 additional weeks after an initial standardized antibiotic treatment with 0.75 topical metronidazole MetroGel. A single site will enroll 40 participants 30 randomized to LACTIN-V and 10 to placebo. 